A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM
Study Identifier:
ALXN2060-TAC-302
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Recruitment Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN2060
Date
Nov 2020 - Nov 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A
Requirements Information
Sex
Female & Male
Age
N/A - N/A
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN2060
Date
Nov 2020 - Nov 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A years
Requirements Information
Protocol Summary
This prospective study is designed to evaluate the efficacy, safety, and tolerability of ALXN2060 (also known as AG10), as well as to establish its pharmacokinetic and pharmacodynamic profile in Japanese participants with symptomatic ATTR-CM administered on a background of stable heart failure therapy.
Trial Locations
Location
Status
Location
Research Site
Bunkyo-ku, Japan, 113-8431
Status
N/A
Location
Research Site
Fukuoka-shi, Japan, 812-8582
Status
N/A
Location
Research Site
Kumamoto-shi, Japan, 860-8556
Status
N/A
Location
Research Site
Kurume-shi, Japan, 830-0011
Status
N/A
Location
Research Site
Matsumoto-shi, Japan, 390-8621
Status
N/A
Location
Research Site
Nagoya-shi, Japan, 466-8560
Status
N/A